POINT Biopharma Global Inc. - Common Stock (NQ:PNT)

N/A UNCHANGED

Last Price Updated: 4:00 PM EST, Dec 26, 2023 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about POINT Biopharma Global Inc. - Common Stock

< Previous 1 2 3 4 Next >

PNT Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of POINT Biopharma Global, Inc. Is Fair to Shareholders

October 03, 2023

From Halper Sadeh LLC

Via Business Wire

A Look Into Healthcare Sector Value Stocks ↗

October 02, 2023

Via Benzinga

5 Value Stocks In The Healthcare Sector ↗

September 11, 2023

Via Benzinga

5 Value Stocks To Watch In The Healthcare Sector ↗

September 04, 2023

Via Benzinga

Amicus Therapeutics Stock Scores Relative Strength Rating Upgrade; Hits Key Benchmark ↗

May 19, 2023

One key metric to look for in a stock is an 80-plus RS Rating. Amicus Therapeutics stock hit that mark, with a jump from 74 to 82 Friday.

Via Investor's Business Daily

Why Shares of Point Biopharma Global Rose Monday ↗

May 15, 2023

The company made a deal to help speed its clinical trials along.

Via The Motley Fool

Earnings Preview: POINT Biopharma Global ↗

March 23, 2023

Via Benzinga

Arlo Technologies, Array Technologies, AirSculpt Technologies And Other Big Stocks Moving Higher On Friday ↗

May 12, 2023

U.S. stocks traded slightly lower, with the Dow Jones dropping around 15 points on Friday. Here are some big stocks recording gains in today’s session.

Via Benzinga

7 Biotech Stocks With Huge Return Potential for Long-Term Investors ↗

April 26, 2023

Although a wildly speculative sector, the low-cost, high-potential biotech stocks to buy and hold may deliver the goods for gamblers.

Via InvestorPlace

Lantheus and POINT Biopharma Announce FDA Grants Fast Track Designation for ¹⁷⁷Lu-PNT2002 for the Treatment of Metastatic Castration Resistant Prostate Cancer

April 24, 2023

From Lantheus Holdings, Inc.; POINT Biopharma Global Inc.

Via GlobeNewswire

7 Thrilling Biotech Stocks for Aggressive Investors to Buy ↗

April 05, 2023

Amid the noise of the global markets recently, these speculative biotech stocks to buy might trade with a mind of their own.

Via InvestorPlace

Earnings Scheduled For March 24, 2023 ↗

March 24, 2023

Companies Reporting Before The Bell • Sunlands Technology (NYSE:STG) is likely to report earnings for its fourth quarter. • Caledonia Mining (AMEX:CMCL) is projected to report earnings for its fourth...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For November 30, 2022 ↗

November 30, 2022

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For December 14, 2022 ↗

December 14, 2022

Via Benzinga

Over $16 Million Bet On Energy Transfer? Check Out These 3 Stocks Insiders Are Buying ↗

November 29, 2022

Although US stocks closed lower on Monday, there were a few notable insider trades.

Via Benzinga

Analyst Ratings for POINT Biopharma Global ↗

November 15, 2022

Over the past 3 months, 5 analysts have published their opinion on POINT Biopharma Global (NASDAQ:PNT) stock. These analysts are typically employed by large Wall Street banks and tasked with...

Via Benzinga

Why Infinity Pharmaceuticals Shares Tumbled Around 38%; Here Are 79 Biggest Movers From Yesterday ↗

November 15, 2022

Gainers Opiant Pharmaceuticals, Inc. (NASDAQ: OPNT) shares surged 113.8% to settle at $20.10 on Monday. Indivior PLC agreed to acquire Opiant Pharmaceuticals for $20.00 per share in cash, plus...

Via Benzinga

Dow Surges 150 Points; Crude Oil Falls Sharply ↗

November 14, 2022

U.S. stocks traded mostly higher toward the end of trading, with the Dow Jones gaining around 150 points on Monday.

Via Benzinga

Why Opiant Pharmaceuticals Shares Are Trading Higher By 115%? Here Are 53 Stocks Moving In Monday's Mid-Day Session ↗

November 14, 2022

Gainers Freight Technologies, Inc. (NASDAQ: FRGT) shares surged 137% to $0.4901 after analysts at Chardan Capital initiated coverage of the stock with a $2.25 price target.

Via Benzinga

Lantheus-POINT Biopharma Ink Strategic Collaboration For Cancer Programs ↗

November 14, 2022

Via Benzinga

12 Health Care Stocks Moving In Monday's Intraday Session ↗

November 14, 2022

Gainers

Via Benzinga

Stocks Cool Off From Last Week's Rally ↗

November 14, 2022

Stocks are starting the week off lower, unable to build off of last week's impressive rally.

Via Talk Markets

Silver Rises Over 1%; Tyson Foods Posts Downbeat Earnings ↗

November 14, 2022

U.S. stocks traded mixed midway through trading, with the Nasdaq Composite dropping around 60 points on Monday.

Via Benzinga

Hasbro, Ascendis Pharma, Coinbase Global And Some Other Big Stocks Moving Lower On Monday ↗

November 14, 2022

U.S. stocks traded mixed, with the Nasdaq gaining more than 50 points on Monday. Here are some big stocks recording losses in today’s session.

Via Benzinga

US Stocks Mostly Lower; Nasdaq Drops Over 100 Points ↗

November 14, 2022

U.S. stocks traded mostly lower this morning, with the Nasdaq Composite dropping more than 100 points on Monday.

Via Benzinga

Lantheus and POINT Biopharma Announce Strategic Collaboration and Exclusive License Agreements for the Commercialization of PNT2002 & PNT2003

November 14, 2022

From Lantheus Holdings, Inc.

Via GlobeNewswire

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

September 27, 2022

Gainers Benitec Biopharma (NASDAQ:BNTC) shares increased by 9.8% to $0.35 during Tuesday's after-market session. The company's market cap stands at $9.0 million.

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For September 16, 2022 ↗

September 16, 2022

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For October 11, 2022 ↗

October 11, 2022

Upgrades

Via Benzinga

Why Vintage Wine Estates Shares Tumbled 40%; Here Are 70 Biggest Movers From Yesterday ↗

September 15, 2022

Gainers AMTD Digital Inc. (NYSE: HKD) shares jumped 311.8% to settle at $189.42 on Wednesday as the stock experienced a resurgence in momentum despite a lack of fundamental news.

Via Benzinga

< Previous 1 2 3 4 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.